Somatostatin Market Dynamics and Analysis by 2031
The Somatostatin Market is expected to register a CAGR of 5.9% from 2023 to 2031, with a market size expanding from US$ XX million in 2023 to US$ XX Million by 2031.
The report is segmented By Type (Octreotide, Lanreotide, Pasireotide); Application (Acromegaly, Neuroendocrine Tumors (NETs), Others); End User (Hospital, Pharmaceutical companies). The global analysis is further broken-down at regional level and major countries. The Report Offers the Value in USD for the above analysis and segments.
Purpose of the ReportThe report Somatostatin Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
- Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
- Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
- Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.
Somatostatin Market Segmentation
Type- Octreotide
- Lanreotide
- Pasireotide
- Acromegaly
- Neuroendocrine Tumors
- Hospital
- Pharmaceutical companies
Strategic Insights
Somatostatin Market Growth Drivers- Rising cases of hormonal disorders: Growing cases of acromegaly and neuroendocrine tumors are key factors driving the somatostatin market. Somatostatin analogues, especially octreotide, have been used primarily for the treatment of hormonal imbalances, whereby they limit the secretion of excessive hormones. Increasing awareness and diagnosis about the disorder would also increase the treatment demand for such agents as somatostatin, thus driving further growth in the market.
- Increased Treatment of Cancer: The introduction of somatostatin analogues for neuroendocrine tumors and other specific malignancies has added impetus to market growth. Such medicines halt tumor growth and relieve symptoms of the malignancy, especially in those whose cancers generally secrete hormone-related factors. Since many patients diagnosed with various cancers are now receiving treatment through the use of somatostatin analogues, the market for these therapies continues to grow worldwide.
- New Drug Formulations: Improved formulations for somatostatin drugs, particularly long-acting injectables and extended-release formulations, have also contributed to growth in the market. Since they require less frequent administration, it improves patient compliance. Convenient treatment options increased adherence to the recommended regimens, which will, in turn, increase the requirement for somatostatin analogs for managing several diseases.
- Transition to long-acting injectable formulations: This is where one observes the trend in the somatostatin market-to long-acting injectable formulations. The comfort derived from fewer injections is linked to reduced non-adherence rates in chronic patients like those with acromegaly and neuroendocrine tumors. Launched by both health care providers and patients, demanding a simplified way to such drugs has assured the form of more extended release formulations in the market.
- Growing Applications in Personalized Medicine: The changing tide that is personalized medicine is the same as what has affected the somatostatin market. Despite the individualized treatment that the greater emphasis is aimed at, analogs of somatostatin are also personalized according to genetic factors and specific disease characteristics. The approach is clearly more targeted in improving effectiveness and thereby enhanced outcome improvement. Hence, somatostatin therapies for rare and complex hormonal disorders are in demand.
- Use of Combination Therapy with Somatostatin: There is a growing trend for the combination of somatostatin analogs with other drugs in the management of neuroendocrine tumors and acromegaly. In addition to these somatostatin analogs, chemotherapy or radiotherapy may supplement the tumors for better therapeutic results and comprehensive management. It opens up these new application areas for somatostatin in oncology and other.
- Emerging Market Growth Opportunities: The driving force for this market in these regions is the countries of Asia and Latin America where the healthcare infrastructure is well-developed and levels of awareness of hormonal imbalance are becoming pronounced. Affordable and accessible treatment modalities are offered in the form of somatostatin analogs in these regions. Therefore, the market will be reaching a larger patient populace but better outcomes for acromegaly and neuroendocrine tumours.
- Emergence of Novel Somatostatin Analogs: It is possible to develop new somatostatin analogues with enhanced efficacy, minimal side effects, and extended duration of action by pharmaceutical companies. New drug delivery systems, for instance, oral formulations or prolonged action injectables, may be explored for patients requiring more convenient methods of treatment. Moreover, new formulations would extend the use of somatostatin analogs beyond conventional therapeutic areas into much wider indications.
Market Report Scope
Key Selling Points
- Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Somatostatin Market, providing a holistic landscape.
- Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
- Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
- Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.
The research report on the Somatostatin Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.
REGIONAL FRAMEWORK
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The market is expected to grow at a CAGR of 5.9%
Increased Treatment of Cancer is the major factors boosting the Somatostatin Market growth
The North America region accounts for highest revenue shareSomatostatin Market?
The final report will duly include market size and projection estimates for all the segments from 2021 to 2031, along with a revenue share and compound annual growth rate (%) for the regional
/
country-wise market wherein 2021-2022 are the historic years, 2023 is considered to be the base year, and the forecast will be provided till 2031, along with CAGR (%)
Asia Pacific is estimated to grow at the highest CAGR over the forecast year (2023 - 2031)
Novartis AG, Sun Pharmaceutical Industries Ltd, Midatech Pharma PLC, Ipsen Pharma, Chiasma Inc. are the major companies operating in the Somatostatin Market
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Somatostatin Market - By Type
1.3.2 Somatostatin Market - By Application
1.3.3 Somatostatin Market - By End User
1.3.4 Somatostatin Market - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. SOMATOSTATIN MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. SOMATOSTATIN MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. SOMATOSTATIN MARKET - GLOBAL MARKET ANALYSIS
6.1. SOMATOSTATIN - GLOBAL MARKET OVERVIEW
6.2. SOMATOSTATIN - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING
7. SOMATOSTATIN MARKET - REVENUE AND FORECASTS TO 2028 - TYPE
7.1. OVERVIEW
7.2. TYPE MARKET FORECASTS AND ANALYSIS
7.3. OCTREOTIDE
7.3.1. Overview
7.3.2. Octreotide Market Forecast and Analysis
7.4. LANREOTIDE
7.4.1. Overview
7.4.2. Lanreotide Market Forecast and Analysis
7.5. PASIREOTIDE
7.5.1. Overview
7.5.2. Pasireotide Market Forecast and Analysis
8. SOMATOSTATIN MARKET - REVENUE AND FORECASTS TO 2028 - APPLICATION
8.1. OVERVIEW
8.2. APPLICATION MARKET FORECASTS AND ANALYSIS
8.3. ACROMEGALY
8.3.1. Overview
8.3.2. Acromegaly Market Forecast and Analysis
8.4. NEUROENDOCRINE TUMORS (NETS)
8.4.1. Overview
8.4.2. Neuroendocrine Tumors (NETs) Market Forecast and Analysis
8.5. OTHERS
8.5.1. Overview
8.5.2. Others Market Forecast and Analysis
9. SOMATOSTATIN MARKET - REVENUE AND FORECASTS TO 2028 - END USER
9.1. OVERVIEW
9.2. END USER MARKET FORECASTS AND ANALYSIS
9.3. HOSPITAL
9.3.1. Overview
9.3.2. Hospital Market Forecast and Analysis
9.4. PHARMACEUTICAL COMPANIES
9.4.1. Overview
9.4.2. Pharmaceutical companies Market Forecast and Analysis
10. SOMATOSTATIN MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Somatostatin Market Overview
10.1.2 North America Somatostatin Market Forecasts and Analysis
10.1.3 North America Somatostatin Market Forecasts and Analysis - By Type
10.1.4 North America Somatostatin Market Forecasts and Analysis - By Application
10.1.5 North America Somatostatin Market Forecasts and Analysis - By End User
10.1.6 North America Somatostatin Market Forecasts and Analysis - By Countries
10.1.6.1 Mexico Somatostatin Market
10.1.6.1.1 Mexico Somatostatin Market by Type
10.1.6.1.2 Mexico Somatostatin Market by Application
10.1.6.1.3 Mexico Somatostatin Market by End User
10.2. EUROPE
10.2.1 Europe Somatostatin Market Overview
10.2.2 Europe Somatostatin Market Forecasts and Analysis
10.2.3 Europe Somatostatin Market Forecasts and Analysis - By Type
10.2.4 Europe Somatostatin Market Forecasts and Analysis - By Application
10.2.5 Europe Somatostatin Market Forecasts and Analysis - By End User
10.2.6 Europe Somatostatin Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Somatostatin Market
10.2.6.1.1 Germany Somatostatin Market by Type
10.2.6.1.2 Germany Somatostatin Market by Application
10.2.6.1.3 Germany Somatostatin Market by End User
10.2.6.2 France Somatostatin Market
10.2.6.2.1 France Somatostatin Market by Type
10.2.6.2.2 France Somatostatin Market by Application
10.2.6.2.3 France Somatostatin Market by End User
10.2.6.3 Italy Somatostatin Market
10.2.6.3.1 Italy Somatostatin Market by Type
10.2.6.3.2 Italy Somatostatin Market by Application
10.2.6.3.3 Italy Somatostatin Market by End User
10.2.6.4 Spain Somatostatin Market
10.2.6.4.1 Spain Somatostatin Market by Type
10.2.6.4.2 Spain Somatostatin Market by Application
10.2.6.4.3 Spain Somatostatin Market by End User
10.2.6.5 United Kingdom Somatostatin Market
10.2.6.5.1 United Kingdom Somatostatin Market by Type
10.2.6.5.2 United Kingdom Somatostatin Market by Application
10.2.6.5.3 United Kingdom Somatostatin Market by End User
10.2.6.6 Rest of Europe Somatostatin Market
10.2.6.6.1 Rest of Europe Somatostatin Market by Type
10.2.6.6.2 Rest of Europe Somatostatin Market by Application
10.2.6.6.3 Rest of Europe Somatostatin Market by End User
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Somatostatin Market Overview
10.3.2 Asia-Pacific Somatostatin Market Forecasts and Analysis
10.3.3 Asia-Pacific Somatostatin Market Forecasts and Analysis - By Type
10.3.4 Asia-Pacific Somatostatin Market Forecasts and Analysis - By Application
10.3.5 Asia-Pacific Somatostatin Market Forecasts and Analysis - By End User
10.3.6 Asia-Pacific Somatostatin Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Somatostatin Market
10.3.6.1.1 Australia Somatostatin Market by Type
10.3.6.1.2 Australia Somatostatin Market by Application
10.3.6.1.3 Australia Somatostatin Market by End User
10.3.6.2 China Somatostatin Market
10.3.6.2.1 China Somatostatin Market by Type
10.3.6.2.2 China Somatostatin Market by Application
10.3.6.2.3 China Somatostatin Market by End User
10.3.6.3 India Somatostatin Market
10.3.6.3.1 India Somatostatin Market by Type
10.3.6.3.2 India Somatostatin Market by Application
10.3.6.3.3 India Somatostatin Market by End User
10.3.6.4 Japan Somatostatin Market
10.3.6.4.1 Japan Somatostatin Market by Type
10.3.6.4.2 Japan Somatostatin Market by Application
10.3.6.4.3 Japan Somatostatin Market by End User
10.3.6.5 South Korea Somatostatin Market
10.3.6.5.1 South Korea Somatostatin Market by Type
10.3.6.5.2 South Korea Somatostatin Market by Application
10.3.6.5.3 South Korea Somatostatin Market by End User
10.3.6.6 Rest of Asia-Pacific Somatostatin Market
10.3.6.6.1 Rest of Asia-Pacific Somatostatin Market by Type
10.3.6.6.2 Rest of Asia-Pacific Somatostatin Market by Application
10.3.6.6.3 Rest of Asia-Pacific Somatostatin Market by End User
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Somatostatin Market Overview
10.4.2 Middle East and Africa Somatostatin Market Forecasts and Analysis
10.4.3 Middle East and Africa Somatostatin Market Forecasts and Analysis - By Type
10.4.4 Middle East and Africa Somatostatin Market Forecasts and Analysis - By Application
10.4.5 Middle East and Africa Somatostatin Market Forecasts and Analysis - By End User
10.4.6 Middle East and Africa Somatostatin Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Somatostatin Market
10.4.6.1.1 South Africa Somatostatin Market by Type
10.4.6.1.2 South Africa Somatostatin Market by Application
10.4.6.1.3 South Africa Somatostatin Market by End User
10.4.6.2 Saudi Arabia Somatostatin Market
10.4.6.2.1 Saudi Arabia Somatostatin Market by Type
10.4.6.2.2 Saudi Arabia Somatostatin Market by Application
10.4.6.2.3 Saudi Arabia Somatostatin Market by End User
10.4.6.3 U.A.E Somatostatin Market
10.4.6.3.1 U.A.E Somatostatin Market by Type
10.4.6.3.2 U.A.E Somatostatin Market by Application
10.4.6.3.3 U.A.E Somatostatin Market by End User
10.4.6.4 Rest of Middle East and Africa Somatostatin Market
10.4.6.4.1 Rest of Middle East and Africa Somatostatin Market by Type
10.4.6.4.2 Rest of Middle East and Africa Somatostatin Market by Application
10.4.6.4.3 Rest of Middle East and Africa Somatostatin Market by End User
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Somatostatin Market Overview
10.5.2 South and Central America Somatostatin Market Forecasts and Analysis
10.5.3 South and Central America Somatostatin Market Forecasts and Analysis - By Type
10.5.4 South and Central America Somatostatin Market Forecasts and Analysis - By Application
10.5.5 South and Central America Somatostatin Market Forecasts and Analysis - By End User
10.5.6 South and Central America Somatostatin Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Somatostatin Market
10.5.6.1.1 Brazil Somatostatin Market by Type
10.5.6.1.2 Brazil Somatostatin Market by Application
10.5.6.1.3 Brazil Somatostatin Market by End User
10.5.6.2 Argentina Somatostatin Market
10.5.6.2.1 Argentina Somatostatin Market by Type
10.5.6.2.2 Argentina Somatostatin Market by Application
10.5.6.2.3 Argentina Somatostatin Market by End User
10.5.6.3 Rest of South and Central America Somatostatin Market
10.5.6.3.1 Rest of South and Central America Somatostatin Market by Type
10.5.6.3.2 Rest of South and Central America Somatostatin Market by Application
10.5.6.3.3 Rest of South and Central America Somatostatin Market by End User
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. SOMATOSTATIN MARKET, KEY COMPANY PROFILES
12.1. NOVARTIS AG
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. SUN PHARMACEUTICAL INDUSTRIES LTD
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. MIDATECH PHARMA PLC
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. IPSEN PHARMA
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. CHIASMA INC.
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. PEPTRON, INC
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. CRINETICS PHARMACEUTICALS
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. DAUNTLESS PHARMACEUTICALS
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. CAMURUS AB
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. TEVA PHARMACEUTICALS INC,
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
12.11. PFIZER INC.
12.11.1. Key Facts
12.11.2. Business Description
12.11.3. Products and Services
12.11.4. Financial Overview
12.11.5. SWOT Analysis
12.11.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
1.Novartis AG
2.Sun Pharmaceutical Industries Ltd
3.Midatech Pharma PLC
4.Ipsen Pharma
5.Chiasma Inc.
6.Peptron, Inc
7.Crinetics Pharmaceuticals
8.Dauntless Pharmaceuticals
9.Camurus AB
10.Teva Pharmaceuticals Inc,
11.Pfizer Inc.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For